Search - tctmd.com

Displaying 161 - 180 of 336

Sort: Relevancy | Date

News Daily News

Hemodynamic Deterioration Post-SAVR: Dysmetabolic Profile, Calcification Could Be Early Warning Signs

Caitlin E. Cox

July 10, 2018

SAFE-MANTA: Large-Bore Vascular Closure Device Achieves Fast Hemostasis With Few Complications

Michael O'Riordan

June 23, 2018

News Daily News

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Michael O'Riordan

June 20, 2018

News Daily News

Burden of Anticoagulation Can Be Reduced in Some Patients With Mechanical Valves

L.A. McKeown

June 12, 2018

News Conference News EuroPCR 2018

NOTION: TAVR in Low-Risk Patients Maintains Its Momentum Through 6 Years

Caitlin E. Cox

May 24, 2018

News Conference News EuroPCR 2018

Embolic Protection in TAVR: Signs of Benefit, but Road Map for Use Still Uncharted

Caitlin E. Cox

May 23, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2018

Caitlin E. Cox

April 30, 2018

News Conference News SCAI 2018

Longer Hospital Stays After TAVR Associated With Worse Outcomes

L.A. McKeown

April 27, 2018

News Daily News

Delayed Coronary Obstruction After TAVR: Prevalence, Causes, and Solution Explored for Deadly Complication

Yael L. Maxwell

April 02, 2018

News Conference News CRT 2018

Ticagrelor: Better Platelet Blockade Post-TAVR?

Michael O'Riordan

March 07, 2018

News Conference News CRT 2018

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Michael O'Riordan

March 05, 2018

News Daily News

Combining Frailty Index With Existing Risk Models Improves Mortality Prediction in TAVR

L.A. McKeown

February 22, 2018

News Daily News

Existing Neurocognitive Deficits Cloud Interpretation of Post-TAVR Changes: SENTINEL Analysis

Caitlin E. Cox

February 05, 2018

News Daily News

Surprising Rate of Cardiac Amyloidosis in TAVR Patients Poses Tough Questions for Diagnosis, Decision-Making

Michael O'Riordan

February 01, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for January 2018

Shelley Wood

January 31, 2018

News Features

Cardiologists Treating Syrian Refugees Call Missions an ‘Addictive’ Passion That Saves Lives

Yael L. Maxwell

January 12, 2018

News Daily News

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Michael O'Riordan

January 09, 2018

News Daily News

REPRISE III in Print: Now With Comparison Between Lotus, Evolut R

Shelley Wood

January 05, 2018

News Daily News

Registry Challenges LVEF Cutoff for AVR, With Implications for Asymptomatic Patients

L.A. McKeown

January 04, 2018

News Daily News

Lotus Valve’s Return to Market in Europe Sees Further Delays

Shelley Wood

November 29, 2017

Advertisement

Hemodynamic Deterioration Post-SAVR: Dysmetabolic Profile, Calcification Could Be Early Warning Signs

SAFE-MANTA: Large-Bore Vascular Closure Device Achieves Fast Hemostasis With Few Complications

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Burden of Anticoagulation Can Be Reduced in Some Patients With Mechanical Valves

NOTION: TAVR in Low-Risk Patients Maintains Its Momentum Through 6 Years

Embolic Protection in TAVR: Signs of Benefit, but Road Map for Use Still Uncharted

TCTMD’s Top 10 Most Popular Stories for April 2018

Longer Hospital Stays After TAVR Associated With Worse Outcomes

Delayed Coronary Obstruction After TAVR: Prevalence, Causes, and Solution Explored for Deadly Complication

Ticagrelor: Better Platelet Blockade Post-TAVR?

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Combining Frailty Index With Existing Risk Models Improves Mortality Prediction in TAVR

Existing Neurocognitive Deficits Cloud Interpretation of Post-TAVR Changes: SENTINEL Analysis

Surprising Rate of Cardiac Amyloidosis in TAVR Patients Poses Tough Questions for Diagnosis, Decision-Making

TCTMD’s Top 10 Most Popular Stories for January 2018

Cardiologists Treating Syrian Refugees Call Missions an ‘Addictive’ Passion That Saves Lives

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

REPRISE III in Print: Now With Comparison Between Lotus, Evolut R

Registry Challenges LVEF Cutoff for AVR, With Implications for Asymptomatic Patients

Lotus Valve’s Return to Market in Europe Sees Further Delays

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content